SCHEMBL15828284

SCHEMBL15828284

Nc1ccnc2c1ncn2[C@@H]1O[C@](F)(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 7/20 0.47
▸ P2RX1 P51575 6/20 0.47
▸ P2RX2 Q9UBL9 4/20 0.47
▸ P2RY1 P47900 7/20 0.46
▸ P2RY2 P41231 6/20 0.46
▸ P2RY11 Q96G91 3/20 0.46
▸ P2RX4 Q99571 5/20 0.44
▸ SRC P12931 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RNASEL Q05823 1/20 0.44
▸ ENPP1 P22413 1/20 0.42
▸ P2RY6 Q15077 1/20 0.42
▸ ADORA2A P29274 1/20 0.42
▸ ADORA2B P29275 1/20 0.42
▸ P2RX6 O15547 1/20 0.42
▸ P2RX5 Q93086 1/20 0.42
▸ P2RX7 Q99572 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15828312 1.00 P2RX3 (0.47) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL15828310 0.86 P2RX1 (0.63) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL15828228 0.86 P2RX1 (0.63) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL16368058 0.83 P2RY1 (0.44) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL16367992 0.82 P2RX3 (0.45) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL15828308 0.82 TGM2 (0.55) P2RY2P2RY6
SCHEMBL15828230 0.82 TGM2 (0.55) P2RY2P2RY6
SCHEMBL15070357 0.82 P2RX3 (0.43) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL15070345 0.81 P2RX3 (0.42) P2RX3P2RX1P2RX2P2RY1P2RY2
SCHEMBL15070351 0.81 P2RX3 (0.43) P2RX3P2RX1P2RX2P2RY1P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9211300-B2 4′-fluoro nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (US) 2015-12-15 — — US disclosed
US-20140178338-A1 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV UNIVERSITE DE MONTPELLIER (FR) 2014-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140178338-A1 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV FBL, HNRNPLL, SLC28A1 P2RX3 1685/4885P2RX1 1842/4885P2RX2 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback